Αποτελέσματα αναζήτησης - Maher Issa

  • Εμφανίζονται 1 - 9 Αποτελέσματα από 9
Περιορισμός αποτελεσμάτων
  1. 1
    Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy

    Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy από Kevin Winthrop, Clifton O. Bingham, Wendy Komocsar, John Bradley, Maher Issa, Rena Klar, Cynthia E. Kartman

    Έκδοση 2019
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  2. 2
    A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

    A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 από Thomas Bieber, Eugen Feist, Alan D. Irvine, Masayoshi Harigai, Ewa Haładyj, Susan Ball, Walter Deberdt, Maher Issa, Susanne Grond, Peter C. Taylor

    Έκδοση 2022
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Revisão
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  3. 3
    Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials

    Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials από Brett King, Catherine Maari, Edward Lain, Jonathan I. Silverberg, Maher Issa, Katrin Holzwarth, Dennis Brinker, Tracy Cardillo, Fabio P. Nunes, Eric L. Simpson

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  4. 4
    Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

    Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated d... από Peter C. Taylor, Tsutomu Takeuchi, Gerd R Burmester, Patrick Durez, Josef S Smolen, Walter Deberdt, Maher Issa, Jorge Ross Terrés, Natalia Bello, Kevin Winthrop

    Έκδοση 2021
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Revisão
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  5. 5
    Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials

    Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials από Masayoshi Harigai, Tsutomu Takeuchi, Josef S Smolen, Kevin Winthrop, Atsushi Nishikawa, Terence Rooney, Chadi Saifan, Maher Issa, Yoshitaka Isaka, Naotsugu Akashi, Taeko Ishii, Yoshiya Tanaka

    Έκδοση 2019
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  6. 6
    Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

    Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications από Peter C. Taylor, Thomas Bieber, Rieke Alten, Torsten Witte, James Galloway, Walter Deberdt, Maher Issa, Ewa Haładyj, Inmaculada de la Torre, Susanne Grond, Andreas Wollenberg

    Έκδοση 2023
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  7. 7
    Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials

    Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials από Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin‐Weller, Diamant Thaçi, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth, Jacob P. Thyssen

    Έκδοση 2022
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  8. 8
    Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

    Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis από Peter C. Taylor, Michael E. Weinblatt, Gerd R Burmester, Terence Rooney, Sarah Witt, Chad D. Walls, Maher Issa, Claudia A. Salinas, Chadi Saifan, Xin Zhang, Anabela Cardoso, Miguel Á. González‐Gay, Tsutomu Takeuchi

    Έκδοση 2019
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  9. 9
    Infections in baricitinib clinical trials for patients with active rheumatoid arthritis

    Infections in baricitinib clinical trials for patients with active rheumatoid arthritis από Kevin Winthrop, Masayoshi Harigai, Mark C. Genovese, Stephen Lindsey, Tsutomu Takeuchi, Roy Fleischmann, John Bradley, Nicole L Byers, David L. Hyslop, Maher Issa, Atsushi Nishikawa, Terence Rooney, Sarah Witt, Christina Dickson, Josef S Smolen, Maxime Dougados

    Έκδοση 2020
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:

Εργαλεία αναζήτησης: